BAFF serum levels in myasthenia gravis: effects of therapy

Amelia Evoli, Flavia Scuderi, Emanuela Bartoccioni, Pe Alboini

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

13 Citazioni (Scopus)

Abstract

B-lymphocyte activating factor (BAFF) is a key survival factor for B lymphocytes. Myasthenia gravis (MG) is an antibody-mediated disease of neuromuscular transmission. Most MG patients have serum antibodies against the nicotinic acetylcholine receptor (AChR). Anti-AChR positive MG is associated with thymus alterations, such as follicular hyperplasia and thymoma. The aim of our study was to evaluate serum BAFF levels in MG patients in different phases of their disease and the effects of therapy. We tested serum samples from 66 MG patients. No patient had anti-muscle specific tyrosine kinase (MuSK) antibodies. BAFF levels were measured by quantitative ELISA. Mean serum BAFF levels were significantly higher in the MG population than in controls. We confirm previous observations that serum BAFF levels are increased in MG, although with no relation with disease severity. In MG patients under IS therapy BAFF mean level was significantly decreased in comparison with the untreated population and controls.
Lingua originaleEnglish
pagine (da-a)2284-2285
Numero di pagine2
RivistaJournal of Neurology
Volume258
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • B-Cell Activating Factor
  • Biological Markers
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Immunosuppressive Agents
  • Myasthenia Gravis
  • Thymectomy

Fingerprint Entra nei temi di ricerca di 'BAFF serum levels in myasthenia gravis: effects of therapy'. Insieme formano una fingerprint unica.

Cita questo